New drug combo tested in fight against deadly pancreatic cancer
NCT ID NCT06646055
Summary
This study is testing the safety and effectiveness of two new immunotherapy drugs (AK112 and Cadonilimab) when given with standard chemotherapy as the first treatment for metastatic pancreatic cancer. It involves 110 adults with advanced pancreatic cancer who have not yet received treatment for their metastatic disease. The main goals are to see how well the combination works to shrink tumors and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.